Roanna Ruiz

Stock Analyst at Leerink Partners

(0)
# 4564
Out of 5,356 analysts
77
Total ratings
38.46%
Success rate
-14.72%
Average return
21 Stocks
Name Action PT Current % Upside Ratings Updated
AKBA Akebia Therapeutics
Initiates Coverage On: Outperform
7
3.69 89.7% 1 Apr 28, 2025
XERS Xeris Biopharma Hold...
Maintains: Outperform
5 6
4.46 34.53% 5 Mar 7, 2025
CRMD Cormedix
Initiates Coverage On: Outperform
18
13.2 36.36% 1 Mar 7, 2025
LXRX Lexicon Pharmaceutic...
Downgrades: Market Perform
1
0.72 38.89% 1 Mar 4, 2025
VIR Vir Biotechnology
Maintains: Outperform
18 20
5.17 286.85% 4 Jan 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
26 27
13.46 100.59% 4 Jan 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
12 13
3.56 265.17% 3 Oct 25, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
14
3.65 283.56% 1 Apr 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
330
319.8 3.19% 1 Feb 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
58
32.07 80.85% 1 Aug 15, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Market Perform
25
68.94 -63.74% 1 Apr 11, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
9 2
n/a n/a 4 Apr 4, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Market Perform
49
7.18 582.45% 10 Feb 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
12 13
4.11 216.3% 7 Jan 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Perform
8 6
3.19 88.09% 6 Jan 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
19
19.51 -2.61% 1 Dec 20, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
110 120
80.44 49.18% 3 Nov 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Perform
75 50
6.08 722.37% 7 Nov 3, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
23 27
n/a n/a 7 Oct 25, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Perform
60 40
11.79 239.27% 6 Oct 19, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
720 80
n/a n/a 3 Jul 14, 2022